Skip to main content
. 2023 Feb 7;24(4):3263. doi: 10.3390/ijms24043263

Figure 8.

Figure 8

The diagram demonstrates the pathway whereby HBV stimulates PCLAF tv1 splicing by decreasing SRSF2 and contributes to sorafenib resistance in HCC by preventing ferroptosis. HBV promotes PCLAF tv1 splicing by inhibiting SRSF2. Sorafenib therapy induces TfR1-Fe2+-induced ferroptosis while suppressing GPX4-suppressed ferroptosis in HCC. HBV inhibits ferroptosis via the SRSF2/PCLAF tv1 pathway, which acts on both the TfR1-Fe2+ and the GPX4 pathways and hence mediates sorafenib resistance.